Completely revised and updated for 2011, the Physicians¡¯ Cancer Chemotherapy Drug Manual 2011 is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens¡ªboth on- and off-label¡ªfor the treatment of all the major cancers.
Special Features Include:
¡öRevised to reflect rapid advances in the field, incorporating treatment strategie and new drugs like Cabazitaxel, Ofatumumab, Pazopanib, and Pralatrexate.
¡öA specific chapter focused on profiling antiemetic drug and antiemetic treatment regimens.
¡öDiagrams of drug structures and pathways for each agent.
¡öOffers a comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages.
¡öCovers toxicity and drug¨Cdrug interactions.
¡öA section on chemotherapy regimens for all major cancers.
¡öProvides an overview of the basic principles of cancer drug therapy.
Contains an easy to load and use CD-ROM version.
Mobile versions of Physicians¡¯ Cancer Chemotherapy Drug Manual are also available for iPhone, iPod Touch, iPad, Android, Blackberry, Palm, Symbian and Windows Mobile.
TABLE OF CONTENTS
Chapter 1 Principles of Cancer Chemotherapy
Chapter 2 Chemotherapeutic and Biologic Drugs
Chapter 3 Guidelines for Chemotherapy and Dosing Modifications
Chapter 4 Common Chemotherapy Regimens in Clinical Practice
Chapter 5 Antiemetic Agents for the Treatment of Chemotherapy-Induced Nausea and Vomiting
ABOUT THE AUTHOR(S)
Edward Chu, MD- Yale University School of Medicine, New Haven, Connecticut
Dr. Edward Chu is Professor of Medicine and Pharmacology at the Yale University School of Medicine. He received his M.D. degree from Brown University, where he also completed his residency training in Internal Medicine Residency. He then went to the National Cancer Institute in Bethesda, MD for fellowship training in Medical Oncology. Following completion of his fellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996, he was recruited to the Yale Cancer Center of the Yale University School of Medicine where he assumed the positions of Director of the VACT Cancer Center, Associate Director of the Yale Cancer Center, and he is co-Director of the Developmental Therapeutics Program at the Yale Cancer Center.
Dr. Chu is well-known for his basic research that has investigated the determinants of resistance to the fluoropyrimidine class of anticancer agents. In particular, his group has made seminal observations on the regulation of expression of thymidylate synthase, a critical target in cancer chemotherapy, with specific focus on elucidating novel translational regulatory mechanisms. In addition, his group is actively involved in developing novel compounds and strategies for the treatment of colorectal cancer as well as other human malignancies. He has worked closely with a number of drug companies to develop novel agents, and these companies include Roche, Bristol-MyersSquibb, Astra Zeneca, Eli Lilly, Pharmacia, GlaxoSmithKline, Imclone, Vion, and Tularik. He serves on the scientific advisory boards of Advrx Pharmaceuticals, Celator, Etex, Phytoceutica, and Eximias, all of which are drug development companies.
He is the author of the Physicians¡¯ Cancer Chemotherapy Drug Manual, which is now in its sixth edition, and this drug manual includes a comprehensive review of all of the main drugs and drug regimens currently used in clinical practice for oncology. He is the founding Editor-in-Chief of the clinical journal Clinical Colorectal Cancer and is the Chairman of the International Colorectal Congress, which is an annual international meeting focusing on management and treatment of colorectal cancer.
Vincent T. DeVita Jr., MD- Yale University School of Medicine, New Haven, Connecticut
Dr. DeVita is Professor of Medicine and Professor of Epidemiology and Public Health at the Yale University School of Medicine in New Haven, CT. He is the former Director of the National Cancer Institute and developed the cure for Hodgkin's Disease and other lymphomas. He is the Director Emeritus at the Yale Cancer Center and has received numerous awards including the Mary and Albert Lasker Prize, the Medal of Honor from the American Cancer Society, the first Pezcoller Award from the European School of Oncology, the Armand Hammer Cancer Prize and the Surgeon General's Exemplary Service Medal. He recently was recognized with the 50th Anniversary Commemorative Award from the Leukemia Society of America and was the recipient of the first Saul Rosenberg Research Award from the Lymphoma Research Foundation of America. Dr. DeVita also served as co-chair of the National Cancer Legislative Advisory Committee for revising the National Cancer Act of 1971.